A Timing Effect of 17-β Estradiol on Atherosclerotic Lesion Development in Female ApoE<sup>−/−</sup> Mice

Differences in size or composition of existing plaques at the initiation of estrogen (E2) therapy may underpin evidence of increased risk of atherosclerosis-associated clinical sequelae. We investigated whether E2 had divergent effects on actively-growing versus established-advanced atherosclerotic...

Full description

Bibliographic Details
Main Authors: Obialunanma V. Ebenebe, Zoe Ashley, Jeffrey R. Erickson, Alison K. Heather
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/13/4710
_version_ 1797563536857104384
author Obialunanma V. Ebenebe
Zoe Ashley
Jeffrey R. Erickson
Alison K. Heather
author_facet Obialunanma V. Ebenebe
Zoe Ashley
Jeffrey R. Erickson
Alison K. Heather
author_sort Obialunanma V. Ebenebe
collection DOAJ
description Differences in size or composition of existing plaques at the initiation of estrogen (E2) therapy may underpin evidence of increased risk of atherosclerosis-associated clinical sequelae. We investigated whether E2 had divergent effects on actively-growing versus established-advanced atherosclerotic lesions. Eight weeks of subcutaneous bi-weekly injections of 3 µg/g 17β-estradiol (<i>n</i> = 18) or vehicle control (<i>n</i> = 22) were administered to female Apolipoprotein null-mice aged 25- or 45 weeks old. Histological assessment of lesion size within the brachiocephalic artery was conducted. Lesion composition was also assessed with acellular, calcification and fibrosis areas measured and other cellular features (intimal thickening, foam cells, lipid pools and cholesterol) scored (0–3) for severity. The comparison showed increased lesion size and calcified area with advancing age but no effect of E2. However, subtle changes in composition were observed following E2. Within the younger group, E2 increased intima thickening and acceleration of calcification. In the older group, E2 increased the thickness of the lesion cap. Therefore, this study shows different effects of E2 depending on the underlying stage of lesion development at the time of initiation of treatment. These divergent changes help explain the controversy of the adverse effects of E2 treatment in cardiovascular disease.
first_indexed 2024-03-10T18:45:00Z
format Article
id doaj.art-ecbe35fde37e4deeb5e774ab6ce5aaf2
institution Directory Open Access Journal
issn 1661-6596
1422-0067
language English
last_indexed 2024-03-10T18:45:00Z
publishDate 2020-07-01
publisher MDPI AG
record_format Article
series International Journal of Molecular Sciences
spelling doaj.art-ecbe35fde37e4deeb5e774ab6ce5aaf22023-11-20T05:35:19ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-07-012113471010.3390/ijms21134710A Timing Effect of 17-β Estradiol on Atherosclerotic Lesion Development in Female ApoE<sup>−/−</sup> MiceObialunanma V. Ebenebe0Zoe Ashley1Jeffrey R. Erickson2Alison K. Heather3Department of Physiology and Heart Otago, School of Biomedical Sciences, University of Otago, Dunedin 9054, New ZealandDepartment of Physiology and Heart Otago, School of Biomedical Sciences, University of Otago, Dunedin 9054, New ZealandDepartment of Physiology and Heart Otago, School of Biomedical Sciences, University of Otago, Dunedin 9054, New ZealandDepartment of Physiology and Heart Otago, School of Biomedical Sciences, University of Otago, Dunedin 9054, New ZealandDifferences in size or composition of existing plaques at the initiation of estrogen (E2) therapy may underpin evidence of increased risk of atherosclerosis-associated clinical sequelae. We investigated whether E2 had divergent effects on actively-growing versus established-advanced atherosclerotic lesions. Eight weeks of subcutaneous bi-weekly injections of 3 µg/g 17β-estradiol (<i>n</i> = 18) or vehicle control (<i>n</i> = 22) were administered to female Apolipoprotein null-mice aged 25- or 45 weeks old. Histological assessment of lesion size within the brachiocephalic artery was conducted. Lesion composition was also assessed with acellular, calcification and fibrosis areas measured and other cellular features (intimal thickening, foam cells, lipid pools and cholesterol) scored (0–3) for severity. The comparison showed increased lesion size and calcified area with advancing age but no effect of E2. However, subtle changes in composition were observed following E2. Within the younger group, E2 increased intima thickening and acceleration of calcification. In the older group, E2 increased the thickness of the lesion cap. Therefore, this study shows different effects of E2 depending on the underlying stage of lesion development at the time of initiation of treatment. These divergent changes help explain the controversy of the adverse effects of E2 treatment in cardiovascular disease.https://www.mdpi.com/1422-0067/21/13/4710atherosclerosiscalcificationfibrosisintimal thickeningmenopauseestrogen therapy
spellingShingle Obialunanma V. Ebenebe
Zoe Ashley
Jeffrey R. Erickson
Alison K. Heather
A Timing Effect of 17-β Estradiol on Atherosclerotic Lesion Development in Female ApoE<sup>−/−</sup> Mice
International Journal of Molecular Sciences
atherosclerosis
calcification
fibrosis
intimal thickening
menopause
estrogen therapy
title A Timing Effect of 17-β Estradiol on Atherosclerotic Lesion Development in Female ApoE<sup>−/−</sup> Mice
title_full A Timing Effect of 17-β Estradiol on Atherosclerotic Lesion Development in Female ApoE<sup>−/−</sup> Mice
title_fullStr A Timing Effect of 17-β Estradiol on Atherosclerotic Lesion Development in Female ApoE<sup>−/−</sup> Mice
title_full_unstemmed A Timing Effect of 17-β Estradiol on Atherosclerotic Lesion Development in Female ApoE<sup>−/−</sup> Mice
title_short A Timing Effect of 17-β Estradiol on Atherosclerotic Lesion Development in Female ApoE<sup>−/−</sup> Mice
title_sort timing effect of 17 β estradiol on atherosclerotic lesion development in female apoe sup sup mice
topic atherosclerosis
calcification
fibrosis
intimal thickening
menopause
estrogen therapy
url https://www.mdpi.com/1422-0067/21/13/4710
work_keys_str_mv AT obialunanmavebenebe atimingeffectof17bestradiolonatheroscleroticlesiondevelopmentinfemaleapoesupsupmice
AT zoeashley atimingeffectof17bestradiolonatheroscleroticlesiondevelopmentinfemaleapoesupsupmice
AT jeffreyrerickson atimingeffectof17bestradiolonatheroscleroticlesiondevelopmentinfemaleapoesupsupmice
AT alisonkheather atimingeffectof17bestradiolonatheroscleroticlesiondevelopmentinfemaleapoesupsupmice
AT obialunanmavebenebe timingeffectof17bestradiolonatheroscleroticlesiondevelopmentinfemaleapoesupsupmice
AT zoeashley timingeffectof17bestradiolonatheroscleroticlesiondevelopmentinfemaleapoesupsupmice
AT jeffreyrerickson timingeffectof17bestradiolonatheroscleroticlesiondevelopmentinfemaleapoesupsupmice
AT alisonkheather timingeffectof17bestradiolonatheroscleroticlesiondevelopmentinfemaleapoesupsupmice